Ion Channels as Promising Therapeutic Targets for Melanoma by Chantôme, Aurélie et al.
Ion Channels as Promising Therapeutic Targets for
Melanoma
Aure´lie Chantoˆme, Marie Potier-Cartereau, Se´bastien Roger, Christophe
Vandier, Olivier Soriani, Virginie Joulin
To cite this version:
Aure´lie Chantoˆme, Marie Potier-Cartereau, Se´bastien Roger, Christophe Vandier, Olivier So-
riani, et al.. Ion Channels as Promising Therapeutic Targets for Melanoma. Yohei Tanaka.
Breakthroughs in Melanoma Research, InTech, pp.429-460, 2011. <inserm-00662370>
HAL Id: inserm-00662370
http://www.hal.inserm.fr/inserm-00662370
Submitted on 24 Jan 2012
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
20 
Ion Channels as Promising  
Therapeutic Targets for Melanoma 
Aurélie Chantôme1, Marie Potier-Cartereau1, Sébastien Roger1,  
Christophe Vandier1, Olivier Soriani2 and Virginie Joulin3 
1Inserm, U921, Tours, 37032 France; Université François Rabelais, Tours, 37032 
2CNRS UMR 6543, Institut de Biologie du Développement et Cancer, 06108 Nice, 
3Inserm U1009, Institut Gustave Roussy, Villejuif, 94805 
France 
1. Introduction 
Even cancer is far from being considered a channelopathy; the field of ion and protein 
channel research in cancer is highly important as an emerging and proven point of 
intervention in disease. Like membrane receptors, ion channels are directly connected with 
and sensitive to the extracellular environment. During the last decade, the number of ion-
channel types expressed in various cancers, including melanoma, was rapidly increased. 
Moreover several ion channels are selectively expressed in aggressive cancers and seem to 
be implicated in metastasis development. The growing number of patents relative to cancer 
therapy targeting channel proteins testifies to the interest of such novel therapeutic 
approaches. 
The physiological significance of ion channels and transporters, as illustrated by the award 
of four Nobel Prizes in Physiology or Medicine (1963; 1991) and Chemistry (1997, 2003), is 
now accepted and established. Unlike transporters and exchangers, channel proteins form a 
pore through membranes allowing the selective passage of one or more ions (e.g. K+, Na+, 
Cl-), molecules (water) or charged atoms, through the lipid bilayer that is impermeable to 
these compounds. The modalities of channel opening or activation are diverse and varied: 
this can be performed by an external molecular stimulus (e.g. ligand), by a mechanical 
stimulus (e.g. cell volume, membrane tension or stretch), by electric stimuli (e.g. changes in 
membrane potential), by an intracellular second messenger (e.g. calcium, cAMP). Thus the 
classification of the channels (IUPHAR classification) is based on the channel activation 
mode and on the selective permeability of molecular species specific to each channel. 
Channel proteins are involved in the control of numerous and various physiological 
functions. Basically, these channels are responsible for a universal property for cellular 
membranes: the existence of resting membrane potential. Ion channels, mainly studied in 
excitable cells like muscle and neurons, are responsible for the transmission of the electric 
signals triggering physiological and biological phenomena such as nerve conduction or the 
cellular phenomenon of excitation - contraction coupling. Ion transporter (Na+/K+-ATPase 
or simply known as sodium pump) is the membrane pump that generates the Na+ and K+ 
gradients across the plasma membrane, driving many physiological processes. Another 
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class of channels, water channels or aquaporins (AQP), allow water molecules to pass 
through the membrane much faster than by simple diffusion through the lipid bilayer, while 
preventing the ions to enter or exit the cell. Finally, channels participate in ionic homeostasis 
and in controlling the shape of the cell by regulating the water flows. 
If in a physiological context, the expression of a particular channel protein is specific in one 
or several tissues or organs, conferring an appropriate biological function, this is not that is 
observed in a tumour context. As a general rule, the cancer cell hijacks a channel's normal 
physiological function to drive certain essential biological functions for tumour 
development (such as proliferation and migration/invasion). Melanoma cells are considered 
to be electrically non-excitable, however they express several types of voltage-activated 
channels (Allen et al., 1997), which is unusual in a non-excitable cell. Because melanocytes 
originated from neural crest-derived precursors, they have retained significant neuronal 
ability. It is therefore not surprising that melanocytes (and a fortiori melanoma cells) can 
express (re-express), ion channels involved in excitatory or sensory functions. 
Data on the level of channel expression in melanocytes versus melanoma cells are highly 
fragmented. Few cases of aberrant expression between melanocytes versus melanoma cells 
have been described. 1) The channel is expressed only in melanoma cells but not in 
melanocytes and it helps in a particular biological function (e.g. enhanced cell migration by 
hijacking the Ca2+ activated K+ channel SK3/KCa2.3). 2) The channel is expressed by non-
malignant melanocytes and is not functional in this context but acquires a function during 
the melanocyte-to-melanoma transition (e.g. anti-apoptotic activity of the P2X7 receptor). 3) 
Inversely, the expression of the channel belonging to transient receptor potential (TRP) 
cation channel subfamily M, TRPM1/Melastatin-1/MLSN-1, is decreased in melanomas 
according to melanoma aggressiveness and is useful as a prognostic marker for melanoma 
metastasis (see for review (Prevarskaya et al., 2007)). However, data and information 
relative to non-malignant melanocyte channel expression or function are scarce and have to 
be continued. Table 1 summarizes the channels expressed by and active in melanoma cells 
and/or melanocyte, and their assigned function. 
Among channels expressed by melanoma cells, some of them contribute to cell survival, like 
the store-operated channel (SOC) and the P2X7R receptor, or to cell proliferation, like the 
SKCa channel SK2/KCa2.2 and the Ca2+-permeable channel TRPM8. Note that the ultimate 
function of those Ca2+-permeable channels is to favour Ca2+ entry into a cell. In melanoma 
cells, several of channels, the voltage-dependent Na+ channel Nav1.6, the SKCa channel 
SK3/KCa2.3 and the water channel AQP1, are involved in cell adherence and migration 
that, in fine, it might confer a metastatic ability. 
Lastly, the significant role of channel proteins in melanomagenesis is reinforced by the 
systematic overexpression of the sigma 1 receptor in many types of cancer including 
melanoma. Even if the sigma 1 receptor is still an enigma, its most well-known action in 
biological systems is the regulation and modulation of many ion channels, including those 
known to be involved in melanoma cell biology, suggesting the existence of tumour specific 
channel macro-complexes. On the other hand, proliferation, apoptosis resistance and 
migration/adhesion of cancer cells are impaired by the modulation of sigma 1 receptor 
activity through mechanisms involving ion channels. By its aberrant expression in 
melanoma, the use of the sigma 1 receptor as a target for an imaging tracer (using a PET 
imaging probe) and for the specific delivery of therapeutic agents (using synthetic sigma 
ligands) is currently the subject of intensive investigation. 
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Expression Ion Channel 
Name 
Ion Channel 
Type 
Biological 
function in 
Melanoma Melanocyte Melanoma 
References 
SOC Store Operated 
Channel 
Cell survival n.d. Murine (B16) 
melanoma cell line 
(Fedida-Metula et al., 
2008; Feldman et al., 
2010) 
P2X7R ATP-gated 
cation-
permeable 
ionotropic 
receptor 
Cell death           
Cell 
invasiveness? 
yes (not 
functional)
Human melanoma 
cell lines & MDA-MB-
435S cell line 
(Bringmann et al., 2001; 
Deli et al., 2007; Greig et 
al., 2003; Ohshima et al., 
2010; Slater et al., 2003; 
Timar et al., 2006; White 
et al., 2005) 
Na+/K+ pump 
(α1 subunit) 
Ion transporter Cell survival       
Cell 
proliferation 
Human metastatic 
melanoma (clinical 
samples & cell lines) 
(Mathieu et al., 2009) 
TRPM8  TRPC Cell death n.d. Human melanoma 
(clinical samples & 
cell lines) 
(Yamamura et al., 
2008a) 
SK2/KCa2.2 K+ channel Cell 
proliferation 
under hypoxia 
yes Human melanoma 
cell lines 
(Chantôme et al., 2009; 
Meyer et al., 1999; 
Tajima et al., 2006) 
EAG K+ channel Cell 
proliferation 
n.d. Melanoma cell lines (Gavrilova-Ruch et al., 
2002; Meyer et al., 1999; 
Pardo & Suhmer, 2008) 
hERG K+ channel Cell 
proliferation, 
migration, 
invasion 
n.d. MDA-MB-435S cell 
line 
(Afrasiabi et al., 2010) 
SK3/KCa2.3 K+ channel Cell migration 
and/or 
invasion 
no Human melanoma 
cell lines 
(Chantôme et al., 2009) 
KCa3.1/IKCa K+ channel Cell migration 
and/or 
invasion? 
yes Human melanoma 
cell lines 
(Schmidt et al., 2010; 
Schwab et al., 1999) 
Nav1.6 Voltage gated 
Na+ channel 
Cell migration 
and/or 
invasion 
n.d.. Human melanoma 
(HTB-26) cell line 
(Carrithers et al., 2009) 
AQP1 Water channel Cell migration 
and/or 
invasion 
n.d. Human (WM115) & 
murine (B16) 
melanoma cell lines 
(Hu & Verkman, 2006; 
Monzani et al., 2009; 
Saadoun et al., 2005) 
Cav 1.3(a) Voltage gated 
Ca2+ channel 
Cell migration 
and/or 
invasion 
n.d. Human (A375M, 
C8161) melanoma cell 
lines 
(Yohem et al., 1991) 
Sigma-1 
receptor 
Chaperone 
protein 
Cell migration  Human melanoma 
(clinical samples & 
cell lines) 
(Friebe et al., 2001; 
Megalizzi et al., 2007) 
Kv1.3 K+ channel Cell adherence n.d.. Human melanoma 
(LOX) cell line 
(Artym & Petty, 2002) 
Pkd2  Non-selective 
cation channel
Cell adherence n.d. Murine melanoma 
cell lines 
(Bian et al., 2010) 
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TASK-3 Two-pore K+ 
channel 
Unknown  yes Human melanoma 
cell lines 
(Pocsai et al., 2006; 
Rusznak et al., 2008) 
TRPM2  TRPC Unknown  no Melanoma cell lines (Orfanelli et al., 2008) 
TRPM1 TRPC Unknown  yes No in human 
melanoma metastases
(Duncan et al., 1998) 
ENaC delta Na+ channel Unknown  n.d. Human melanoma 
cell lines 
(Yamamura et al., 
2008b) 
(a) Expression of Cav 1.3 has been indirectly determined using Verapamil, a Ca2+ channel blocker. 
TRPC: Transient Receptor Potential Channel; n.d.: not determined 
Table 1. Summary of ion channels expressed in melanoma 
Our understanding of the action of channel proteins in cancer has just begun to take shape. 
Despite the advancements over the past two decades in defining the expression and the role 
of channel proteins in melanoma, many questions remain unanswered. For example, can a 
particular channel protein be a marker of a specific phenotype of melanoma? Is there 
particular intracellular signalling machinery involved for an ionic channel tumour function? 
As channel proteins are hijacked from their normal physiological function: Do channel 
proteins adopt a different folded conformation in a tumour context compared to a 
physiological context? Do channels form different protein complexes in a physiological 
context compared to tumour context? Regarding to these two last questions, do channel 
proteins link to a particular membrane tumour environment (e.g. lipid, raft)? Answering the 
last three questions will help design specific therapeutic approaches targeting channel 
proteins, that will make it possible to avoid side effects. 
This review aims to identify the data of the literature that reported expression of proteins 
known to form ion channels and found to be expressed by cutaneous melanoma cells, and, 
whenever possible, to precise the biological function that has been assigned to them in this 
tumour context. A critical analysis on the druggable nature of these channel proteins will be 
presented. The cutaneous malignant melanoma being one of the cancers that has a greater 
metastatic potential, we shall pay a particular attention to the channels participating in the 
motility (migration and invasion) of the cancer cell. With the development of personalized 
targeted therapies, we are entitled to wonder if each channel protein, hijacked from its 
physiological function by the cancer cell, can indeed be considered as relevant therapeutic 
targets. 
2. Ion channels and cell survival and apoptosis 
2.1 Store-operated channels (SOCs) 
Malignant melanoma is characterized by its extreme resistance to cell death-inducing factor 
(Becker et al., 2006; Soengas & Lowe, 2003). The molecular derangement underlying the low 
susceptibility of melanoma cells to apoptosis include an aberrant activation of protein kinase 
PKB/Akt. Indeed, high resting PKB activity in the murine metastatic melanoma clone 
B16BL6, promotes their serum independent growth and protects these cells from apoptosis 
(Assa-Kunik et al., 2003). In contrast, non-tumour cells are sensitive to cell death-inducing 
factors associated to a very low basal activity of PKB (Assa-Kunik et al., 2003). Elevated level 
of PKB activity is a common finding in lesions of advanced melanoma (Dai et al., 2005; 
Slipicevic et al., 2005) and inversely correlates with patient survival (Dai et al., 2005). One of 
the activation pathways of PKB involves the complex calcium (Ca2+)/calmodulin associated 
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(Dong et al., 2007) with functional Store-Operated Channels (SOCs) (Fedida-Metula et al., 
2008). In most non-excitable, cells depletion of endoplasmic reticulum (ER) stores elicits 
sustained Ca2+ influx by SOCs in plasma membrane, defining the major Ca2+ influx pathway 
(Putney, 1986). Following ER depletion, the ER Ca2+ sensor Stim1 forms multimers and 
migrates to ER/plasma membrane junctions where they activate a non-voltage-gated 
channel called Ca2+ release-activated Ca2+ (CRAC) channel, Orai. The CRAC current is 
characterized by a very low single channel conductance, a high Ca2+ selectivity, an inward 
rectification and a complex regulation by both intra and extracellular Ca2+ (Parekh & 
Putney, 2005). 
Ca2+ storage inside the ER is an essential indicator of the cell’s proliferative, metabolic and 
apoptotic status. The retrograde signalling process from ER Ca2+ depletion to store-operated 
Ca2+ entry (SOCE) activation has a central role for many cellular and physiological functions 
(Lewis, 2001). Thus, coordinated regulatory mechanisms must exist in the cell to ensure tight 
control of SOCs function. Among all key regulators of intracellular Ca2+ homeostasis, trans-
mitochondrial Ca2+ transport is one of the most important, particularly in the sub-
plasmalemmal and ER (Demaurex et al., 2009; Parekh, 2008) thanks to the mitochondrial 
uniporter (mCU) (Demaurex et al., 2009; Parekh, 2008; Rizzuto & Pozzan, 2006). In addition 
to regulate Ca2+ homeostasis in these micro-domains, the ability of mitochondria to take up 
and release Ca2+ impacts on SOCE process (Glitsch et al., 2002). More clearly, mitochondria 
have been shown to modulate SOCE by buffering incoming Ca2+, so this dissipation of high 
Ca2+ micro domains is critical for sustained Ca2+ entry (Demaurex et al., 2009; Gilabert et al., 
2001; Gilabert & Parekh, 2000; Malli et al., 2003; Parekh, 2003, 2008). In order for 
mitochondria to buffer efficiently Ca2+ and to prevent the slow Ca2+-dependant inactivation, 
it was proposed Ca2+ entry attracts mitochondria to plasma membrane, close to the Ca2+ 
entry channel (Quintana et al., 2006; Varadi et al., 2004). 
Recent study on melanoma cells, suggests a functional relevance for Ca2+ driven growth and 
survival-promoting signalling in these tumour cells due to a control of SOCE by 
mitochondria (Feldman et al., 2010). The authors have shown that coupling of mitochondria 
to SOCE sustains constitutive activation of PKB/Akt pathway leading to increase melanoma 
cells survival (Fig. 1). When they compared SOCE in malignant melanoma cells B16BL6-8 
and in non-malignant cells Kb30 B16BL6, they described, only for malignant melanoma cells, 
a robust SOC function (without over-expression of Orai1 and Stim1) associated with 
accelerated trans-mitochondrial Ca2+ flux (Feldman et al., 2010). Conversely, inhibition of 
the trans-mitochondrial Ca2+ by the antagonist of Na+/Ca2+ exchanger (NCX) decreased 
SOCE (Feldman et al., 2010). This functional coupling allow the maintain of a strong Ca2+ 
fluxes in malignant melanoma cells. Ca2+ is, among others, an essential second messenger 
modulating AKT activity in many types of cells (Deb et al., 2004; Dong et al., 2007; Sandoval 
et al., 2007). AKT kinases, have emerged as critical mediators of signal transduction 
pathways downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase. AKT 
protein is a cardinal node in diverse signalling cascades important in both normal cellular 
physiology and various disease states include cell proliferation and survival, intermediary 
metabolism, angiogenesis, and tissue invasion. Aberrant regulation of these processes result 
in cellular perturbations considered hallmarks of cancer, and numerous studies testify to the 
frequent hyperactivation of AKT signalling in many human cancers (Altomare & Testa, 2005; 
Bellacosa et al., 2004; Testa & Tsichlis, 2005). Recent studies have observed that 
Ca2+/calmodulin may be a regulator of AKT activation and found that activity and 
functions of AKT are directly regulated by the Ca2+ signal (Fig. 1). More precisely, in 
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neutrophils, it has been described that SOCE mediates intracellular alkalinization and 
ERK1/2, AKT phosphorylation (pAKT) (Sandoval et al., 2007). This link was supported by 
the correlation between of trans-mitochondrial Ca2+ flux triggered by SOCs and SOCE itself 
and levels of AKT in malignant vs non-tumour melanoma cells (Feldman et al., 2010). 
Indeed, the high basal AKT activity in malignant melanoma cells is Ca2+ dependant and can 
be reversed by decreasing cytosolic Ca2+ concentration with Ca2+ chelator (Fedida-Metula et 
al., 2008) giving a special importance of SOCE in the control of intracellular Ca2+ 
concentration. Thus, down-regulation of the SOCs regulator Stim1 by shRNA leading to ~ 
ten-fold reduction of SOCE correlated to a significantly decreased of pAKT levels compared 
to control transfected cells (Feldman et al., 2010). The same results have been obtained in 
melanoma tumour cells treated with an antagonist of Na+/Ca2+ exchanger: AKT inactivation 
and the decreased of intracellular Ca2+ concentration coincided with an important SOCE 
reduction (Feldman et al., 2010). Taken together, theses studies showed a real control of 
AKT regulation by a positive feedback loop between trans-mitochondrial Ca2+ transport and 
SOCE leading to strong cell resistance to apoptosis. 
 
 
Fig. 1. AKT activation by mitochondria coupled to store-operated Ca2+ entry. Massive Ca2+ 
entry, following activation of Orai1 by Stim1, facilitates the transmitochondrial Ca2+ flux 
trough the uniporter mCU and exchanger Na+/Ca2+ NCX. This mechanism removes high 
Ca2+ level from the SOCs vinicity (as a Ca2+ buffer) and preventing the Ca2+ dependent slow 
inactivation of CRAC channel.  The ability of mitochondria to buffer sub-plasmalemmal 
Ca2+ sustains a robust Ca2+ entry required for AKT activation leading to increase cell 
survival 
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The role of SOCE and trans-mitochondrial Ca2+ transport present a real potential to develop 
new strategy to control AKT regulation and thus try to modulate tumour aggressiveness 
and death signals in cancer cells. It remains to show that these interesting and promising 
data, which have all been observed in murine cell lines, have a meaning in human 
melanomas.  
2.2 ATP-gated ionotropic P2X7 receptor 
Purine nucleotides, essential components of DNA and RNA, are key elements in replication 
and transcription phenomenon and therefore in cell physiology and proliferation. Among 
all purine nucleotides, Adenosine 5’-Triphosphate (ATP) is also recognized as being the 
fundamental energetic source necessary for all cellular functions. Indeed ATP is a central 
and a precious intracellular molecule to be kept inside the cells. After having been 
confronted to considerable scepticism, Geoffrey Burnstock established the existence of 
intercellular purines signalisations pathways allowed by the release of ATP in the 
extracellular compartment (Burnstock, 1972). Indeed, extracellular purines are known to 
modulate general cellular properties such as cell survival and proliferation, cell 
differentiation and motility through the activation of plasma membrane purinergic 
receptors. These receptors are well known in vertebrates (Burnstock, 2006) and are 
conserved throughout the evolution in lower organisms such as unicellular eukaryotes 
(Fountain et al., 2007), green algae (Fountain et al., 2008), and also in plants (Kim et al., 2006; 
Weerasinghe et al., 2009). 
Extracellular ATP activates plasma membrane G protein-coupled P2Y receptors and/or 
ligand-gated cation-permeable channels (Na+ / Ca2+ / K+) P2X receptors (Burnstock, 2006). 
Among the members of the P2X receptors family, the latest cloned P2X7 receptor (P2X7R) 
(Rassendren et al., 1997; Surprenant et al., 1996) is very unique in its functioning by many 
features, such as 1) its low sensitivity to ATP (North, 2002), 2) its increasing activity, called 
facilitation, under successive or sustained applications of agonist (Roger et al., 2010; Roger et 
al., 2008), and 3) the appearance of a large, non-selective membrane pore after sustained 
stimulations with ATP due to the P2X7-dependent activation of pannexin-1 (Pelegrin & 
Surprenant, 2006). From a physiological point of view P2X7R is expressed in cells from 
immune lineage and its activation by extracellular ATP at concentrations upper than 100 µM 
is considered as an alarming signal, and is a key step in the initiation of the inflammatory 
cascade through the NLP3 inflammasome (Di Virgilio, 2007; Pelegrin, 2008). Pharmacological 
activation of P2X7R is generally associated to membrane permeabilization and blebbing, 
phosphatidyl serine loss of asymmetry, cell swelling, increase of internal Ca2+, loss of 
mitochondrial potential. All these phenomenon were demonstrated to be reversible under 
brief P2X7R activation, and called pseudoapoptosis, but were leading to cell death when 
prolonged stimulation (Mackenzie et al., 2005). This led to the hypothesis that P2X7R were 
cytolytic and that their stimulation or overexpression could be deleterious for cells (Di 
Virgilio et al., 1998; Mackenzie et al., 2005; Surprenant et al., 1996). Surprisingly, it was 
found that P2X7R was expressed at very high levels in several tumours, compared to normal 
tissues (Adinolfi et al., 2002; Raffaghello et al., 2006; Slater et al., 2004a; Slater et al., 2004b; 
Solini et al., 2008; Wang et al., 2004; Zhang et al., 2004) and was even proposed to represent 
an early prostate cancer marker (Slater et al., 2005), while in cervical cancer a decreased 
expression of P2X7R in cancer cells was reported (Li et al., 2006). Several studies indicated 
the overexpression of P2X7R in human (Bringmann et al., 2001; Deli et al., 2007; Slater et al., 
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2003; White et al., 2005) and B16 mouse melanoma (Ohshima et al., 2010). However the role 
of such a receptor in melanoma cell biology remains unclear. 
The most accepted view attributes pro-apoptotic effects of P2X7R stimulation in melanoma 
and non-melanoma skin cancers (Greig et al., 2003; White et al., 2005). This supported the 
use of ATP for the treatment of melanoma (White et al., 2005; White et al., 2009), as it was 
proposed in the 1980’s for other cancers (Rapaport, 1983, 1988; Rapaport et al., 1983). 
Ohshima and coll. (Ohshima et al., 2010) showed that P2X7R is expressed in a B16 mouse 
model of melanoma and was responsible for ATP release from cancer cells induced by -
irradiation. They also suggested that this release of ATP in the extracellular compartment of 
tumours could play as a signalling molecule between cancer cells and adjacent parenchymal 
cells. This should be further investigated. 
In another study, P2X7R was reported to be overexpressed and functional in melanoma cells 
compared to normal melanocytes in which it was non-functional. In melanoma, P2X7R was 
associated to the overexpression of type 2 ryanodine receptor (RyR2) and contrarily to the 
general consensus; it displayed anti-apoptotic effects (Deli et al., 2007). The same study 
showed P2X7R proteins expression in melanoma cell nucleus. Therefore this raises the 
possibility that activation of P2X7R in melanoma could be responsible for different cell fate, 
depending on its subcellular localization and/or protein association. It is also possible that 
P2X7R proteins may be dysfunctional in some cases as it was proposed in chronic lymphocytic 
leukaemia with the overexpression of the loss-of-function mutant allele A1513C (Wiley et 
al., 2002) or in cervical cancers in which P2X7R is overexpressed under its truncated form 
that is inefficient to permeabilise cell membrane (Feng et al., 2006a; Feng et al., 2006b). 
All these studies mainly focused on the regulation of cell proliferation / apoptosis and 
P2X7R participation in other parameters such as cancer cell invasiveness have not yet been 
assessed in melanoma. A recent study performed in MDA-MB-435s cancer cells showed the 
expression of the full length and fully functional P2X7R and that its activation was leading 
to the SK3-dependent increase in cell motility, probably through the increase of internal 
Ca2+, and was dramatically increasing extracellular matrix proteolysis through the release of 
active cystein cathepsins (Jelassi et al., 2011). Indeed further studies will be necessary to 
really establish the role of such intriguing receptors in melanoma as well as in other cancer 
types. Depending on this, either the use of agonists, or recent antagonists, mainly developed 
for the treatment of inflammatory diseases (Romagnoli et al., 2008) could be considered for 
the treatment of melanoma. 
2.3 Calcium channel TRPM8 
The TRPM8 (express transient receptor potential melastatin subfamily member 8) channel, a 
cold-temperature receptor, belongs to the transient receptor potential (TRP) channel 
superfamily. It has been identified in sensory neuron as a Ca2+-permeable cation channel 
that is stimulated by temperatures below 28°C and is modulated in a voltage channel-
dependent fashion. After activation by temperature decrease or cooling compounds such as 
menthol or eucalyptol, TRPM8 induces membrane depolarization by Ca2+ influx. In addition 
to transduction of thermal stimuli in the peripheral nervous system, TRPM8 serves other 
biological roles according to its expression in other tissues (e.g. bladder, male genital tract) 
(Stein et al., 2004). It is also observed that TRPM8 expression increases dramatically in many 
cancer types including cutaneous melanoma (Yamamura et al., 2008a). Yamamura and coll. 
demonstrated that TRPM8 activation by agonists suppresses human melanoma cell viability 
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(Yamamura et al., 2008a). Interestingly, numerous classical TRPM8 agonists are known, in 
addition to novel agonists (Bodding et al., 2007) that may be useful to treating most cancers 
in which TRPM8 channel is overexpressed in comparison to the corresponding normal 
tissue. Because of their inocuity, they represent a formidable pharmacological tool to 
evaluate this channel as target to melanoma therapy. 
2.4 The sodium pump (Na+/K+-ATPase) 
The sodium pump (Na+,K+-ATPase) is a plasma membrane binary complex with enzymatic 
activity that moves three Na+ ions out of, and two K+ ions into, the cell for each ATP that is 
hydrolysed. In humans, the Na+ pump acts to maintain resting membrane potential, is 
useful as transporter, regulate intracellular ion homeostasis, and regulate cellular volume. 
The human sodium pump is composed of two essential protein subunits, the catalytic α-
subunit that has four isoforms (α1–α4) and the auxiliary β-subunit that has three isoforms 
(β1–β3) (Morth et al., 2011), and an optional regulatory γ-subunit with tissue-specific 
expression. The α1 and β1 subunits of the Na+,K+-ATPase are ubiquitously expressed and 
form α1β1 complex in most tissues, the other α and β subunits exhibit a restricted pattern of 
expression specific to each subunit (Morth et al., 2011). Many cancer types over-express the 
different α sub-units, including melanoma (Boukerche et al., 2004). Interestingly, Mathieu 
and coll. have recently shown that more than 30% of all human melanomas, 50% of all 
melanoma metastases and 72% of brain melanoma metastases over-expressed sodium pump 
α1 subunit compared with only 5% of naevi. Interestingly the α1 subunit expression 
significantly correlates with tumour thickness and disease progression (Mathieu et al., 2009). 
Moreover, using the pharmacological drug UNBS1450 and genetic approach, the authors 
demonstrated that functional inhibition of α1 subunit in melanoma cell lines impaired cell 
growth, induced cell death, and improved the survival of immunodeficient mice bearing 
human melanoma brain metastases. Note that UNBS1450, a hemi-synthetic cardiotonic 
steroid, which binds to the α1 subunit of the sodium pump, has entered Phase I clinical trials 
in cancer patients. 
3. Ion channels and melanoma cell proliferation 
Information on ion channels involvement in melanoma cell proliferation is highly 
fragmented and unclear, although early data were published almost three decades. This 
research is still in its beginnings. Indeed there is good evidence that at least K+ channels are 
involved in the cell cycle progression and proliferation in many cancer cells of different 
origins (Villalonga et al., 2007). Several hypotheses could explain the involvement of K+ 
efflux in the control of the cell cycle: Ca2+ signalling, membrane potential and cell volume 
(Villalonga et al., 2007). In melanoma cell lines, the inhibition of K+ channel activity by 
unspecific K+ channel blockers leads to membrane depolarization and an arrest of cell 
proliferation (Gavrilova-Ruch et al., 2002; Lepple-Wienhues et al., 1996; Nilius & Wohlrab, 
1992). In addition, membrane depolarization of melanoma cells induced by elevated 
extracellular K+ concentration inhibited proliferation of cycling cells (Nilius & Wohlrab, 
1992). Nilius et al. (Nilius et al., 1993), proposed that in human melanoma cells 
overexpression of K+ channels leads to hyperpolarisation as a result of the efflux of cations 
from the cell interior, which subsequently causes inward movement of Ca2+ ions to maintain 
the membrane potential. The role of Ca2+ in the transition from the G1 to the S phase during 
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mitosis in mammalian cells is well documented and Ca2+ acts as a pacemaker that initiates 
the timing of cell cycle transitions (Santella et al., 2005). Interestingly, recent evidence 
suggests that in addition to their K+ conductance, a non-pore function of KCa3.1/SK4/IKCa 
and Eag1 could be observed by interacting directly with cell signalling network involved in 
the control of cell proliferation in non-cancer cells (Hegle et al., 2006; Millership et al., 2010). 
Furthermore, mutation that eliminates Eag1 ion permeation fails to completely abolish 
xenograft tumour formation, indicating that Eag1 contributes to tumour progression 
independently of its primary function as an ion channel (Downie et al., 2008). 
3.1 Small and intermediate calcium-activated potassium channel (SKCa and IKCa) 
The calcium-activated K+ channel KCa family encompasses Small- (SKCa) and Intermediate- 
(IKCa/KCa3.1/SK4) conductance calcium activated K+ channels. Functional SKCa channels 
result mostly in a homo or heteromeric assemblies of four subunits. There are three isoforms 
of SKCa subunits, named SK1/KCa2.1, SK2/KCa2.2, SK3/KCa2.3, which associate to form 
homo- or hetero-tetramers (Ishii et al., 1997; Monaghan et al., 2004). SK1, SK2 and SK3 
proteins are principally expressed in central neurons where SKCa channels have a 
fundamental role in regulating neuronal excitability (Bond et al., 2005). Indeed, they 
hyperpolarize the plasma membrane and they contribute to the long lasting 
afterhyperpolarisation that follows an action potential (Bond et al., 2005). SK2 and SK3, in 
contrast to SK1, are not restricted to neuronal tissues and SK3 protein is expressed in 
vascular and visceral smooth muscle-rich tissues (Chen et al., 2004). In these muscles the 
activation of SK3 channel induces hyperpolarisation that respectively regulates muscle tone 
and cell motility (Chen et al., 2004; Herrera et al., 2003; Taylor et al., 2003). This membrane 
function of SK3 channel, hyperpolarisation that is dependent of K+ flux, is that you except to 
find for K+ channels in excitable cells like muscle and neuronal cells. 
SKCa channel activity is independent to voltage but sensitive to elevated Ca2+ 
concentrations. Involvement of theses channels have been investigated in melanoma cells 
because their resulting K+ efflux could provide a membrane hyperpolarisation necessary to 
cell proliferation. In agreement with the reported restricted expression pattern of SK1 
channel mainly found in neuronal tissues, transcript was no detected in melanoma cells and 
in normal human epidermal melanocytes NHEM (Chantôme et al., 2009; Tajima et al., 2006). 
In contrast, SK2 transcripts were always detected in melanocyte and melanoma cell lines but 
electrophysiological analyses revealed that SK2 channels were not functional in the three 
melanoma cell lines tested (IGR-1, SKmel-28 and 518A2) (Chantôme et al., 2009; Meyer et al., 
1999; Tajima et al., 2006). Interestingly, SK2 transcripts level and KCa (SK2 et KCa3.1) 
currents are increase under hypoxia and only in this condition, apamin application, a non 
specific pore blocker of SK2, reduced cell proliferation rates in IGR-1 melanoma cells 
(Tajima et al., 2006). SK3 transcripts and functional SK3 channels have been found in several 
melanoma cells but not in untransformed melanocytes (Chantôme et al., 2009; Tajima et al., 
2006). It has been clearly demonstrated that SK3-dependent efflux regulates membrane 
potential in 518A2 and SKmel-28 melanoma cells (Chantôme et al., 2009). However, 
enforced production of SK3 channels in SK3 non-expressing melanoma cells or specific SK3 
channel extinction in 518A2 melanoma cells has no effect on their cell proliferation 
(Chantôme et al., 2009). 
At last, KCa3.1/SK4 channels are widely expressed in a variety of non-excitable tissue and 
have been involved in cell cycle progression of different type of cancer cells such as breast, 
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pancreatic, and endometrial cancer cells (Jager et al., 2004; Ouadid-Ahidouch et al., 2004; 
Wang et al., 2007). KCa3.1/SK4 transcripts are detected in NHEM and in all melanoma cell 
lines tested and electrophysiological analyses shown strong KCa3.1/SK4 currents 
(Chantôme et al., 2009; Meyer et al., 1999; Tajima et al., 2006). Application of charybdotoxin, 
an unspecific KCa3.1/SK4 blocker, inhibits or not cell proliferation of IGR-1 cells according 
to studies (Gavrilova-Ruch et al., 2002; Tajima et al., 2006). A more recent study using 
TRAM-34, a specific inhibitor of KCa3.1/SK4 channel (Wulff et al., 2000), demonstrated that 
this channel is not involved in cell proliferation of SKmel-28 melanoma cells despite actively 
regulated membrane polarization (Chantôme et al., 2009). Note that, TRAM-34 inhibits both 
K+ conductance and non-pore function of KCa3.1/SK4 channels (Millership et al., 2010). In 
conclusion, even if membrane polarization is in part controlled by SK3 and KCa3.1/SK4 
efflux in melanoma cell lines, it seems not involved or not sufficient to modulate their cell 
proliferation. It will be interesting to precise the mechanism through SK2 under hypoxia 
condition promotes cell proliferation of melanoma cells. 
3.2 Voltage-gated potassium channels and Eag1 
Voltage gated K+ channels (VGKC) represent the largest ion channel family. Functional 
channels result from the association of alpha- (pore) and beta- (accessory) subunits (Pongs & 
Schwarz, 2010). Alpha subunits co-assemble in tetramers, each subunit containing a 
“voltage-sensor” determining the voltage threshold for channel activation. VGKC are 
divided up in 12 families containing up to 8 members, totalizing 40 different cloned alpha 
subunit isoforms (Gutman et al., 2003). Functional channels result from the association of 
different members inside a given family, giving rise to an extraordinary large panel of 
different channels with various gating kinetics and pharmacological properties. The set of 
alpha subunit expressed by a given cell type defines in fact its electrical signature and its 
function. VGKC are widely expressed in excitable and non-excitable cells and participate to 
the control of membrane resting potential and action potential repolarisation and firing 
frequency. Not surprisingly, these channels are involved in a large variety of physiological 
processes including neuronal excitability, hormone secretion, muscle contraction, and 
cardiac rhythm. Interestingly, several VGKC are abnormally expressed in cancer versus 
healthy tissues, including melanoma. Their initial function is then hijacked to participate to 
the tumour phenotype. We will more particularly focus on Eag1 and its putative role in cell 
proliferation, and hERG and Kv1.3 and their putative role in cell migration / invasion (see 
below). 
Eag1 (ether-à go-go) channel also known as KCNH1 (gene) or Kv10.1 (protein) are a voltage-
gated channel that regulates permeation of ion in response to changes in the membrane 
potential. Eag1 gives rise to a slowly activating and non-inactivating current in heterologous 
expression systems. Eag1 is mainly expressed in the brain {Martin, 2008 #283; (Martin et al., 
2010). In the periphery, Eag1 expression is restricted to cell populations of the 
gastrointestinal tract, pancreas and male reproductive system (Hemmerlein et al., 2006; 
Pardo & Suhmer, 2008). 
No information about its expression in melanocyte has been reported. While its function in 
the brain remains unknown, Eag1 has been involved in skeletal muscle development, the 
channel being transiently expressed in the onset of myoblasts fusion (Bijlenga et al., 1998). 
Remarkably, Eag1 is associated with tumours development in patients and animals. Eag1 is 
significantly overexpressed in up to 70% of tumour samples and cell lines (Hemmerlein et 
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al., 2006; Pardo et al., 1999; Pardo & Suhmer, 2008), including melanoma cells (Meyer et al., 
1999). The mechanisms inducing Eag1 overexpression in cancer cells is still unknown, but it 
has been reported that immortalization of cells by oncogenes such as papillomavirus 
provokes Eag1 expression (Diaz et al., 2009). The molecular and functional links between 
Eag1 expression and cancer development has been intensively scrutinized. Eag1 inhibition 
by either siRNA silencing or functional antibodies decreases cancer cell proliferation in vitro 
(Weber et al., 2006) and in vivo (Gomez-Varela et al., 2007). Moreover, Eag1 expression 
increases neovascularisation and enhances cell resistance to hypoxia by increasing Hif 
activity (Downie et al., 2008). Interestingly, point mutation abolishing Eag1 pore function 
failed to completely abolish xenograft tumour formation by transfected cells, indicating that 
Eag1 contributes to tumour progression independently of its primary function as an ion 
channel. Other study proposes that Eag-1 channels participate to cell-cycle progression in 
IGR-1 melanoma cells by using different unspecific blockers of K+ channels (Gavrilova-Ruch 
et al., 2002). It will be interesting to confirm this result by using specific siRNA directed to 
Eag1 channels as it was already used previously in other type of cancer cell lines (Weber et 
al., 2006). Altogether, these data suggest that Eag1 represent a very promising target in 
melanoma treatment. It is noteworthy that Eag-1 is not expressed in the heart, rendering 
possible the use of specific Eag-1 blockers. However good selectivity vs the hERG cardiac 
channel, of the same family, (KCNH2) should be taken into account. In this perspective, 
functional antibodies would represented an interesting perspective to target Eag-1 in 
tumours, neither altering the cardiac hERG channel, nor the Eag-1 channels expressed in the 
CNS because of the brain blood barrier (Gomez-Varela et al., 2007). 
4. Ion channels and melanoma cell migration / invasion / adhesion 
With the occurrence of metastasis, the prognosis of melanoma is poor, with limited available 
treatments and an expected survival less than one year. Knowing that the metastasis 
occurrence involves many cellular processes including cell deformation, invasion, 
migration, adhesion and homing in the "metastatic" site, it is important to define the specific 
molecular mechanisms governing each of these various steps. This is especially important 
that no new treatment of metastatic melanoma has been validated for decades. Intensive 
research in this area has identified at least a type of ion channels involved in melanoma cell 
migration, the calcium-activated potassium channel SK3, and channels that contributes to 
melanoma cell migration / invasion / adhesion. 
4.1 SK3 channel 
Among SKCa channels, SK3 channel was found to promote breast and colon epithelial 
cancer cells and, melanoma cells migration by hyperpolarizing plasma cell membrane 
(Chantôme et al., 2009; Potier et al., 2006; Potier et al., 2010). As mentioned above, SK3 
protein is produced in melanoma cells but not in untransformed melanocytes (Chantôme et 
al., 2009). This is not surprising if you consider that melanocytes share a neural crest origin 
with most SK3-expressing mature cells, i.e. neurons, glial cells and endocrine cells. Re-
expression of embryonic genes during cancer has been widely described (Monk & Holding, 
2001). It is therefore plausible that SK3 channel expression during melanoma malignancy 
corresponds to the re-expression of an embryonic gene expressed by a neural progenitor 
common to neurons and melanocytes (Klein et al., 2007; Rasheed et al., 2005). 
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We have reported that SK3 channel promotes melanoma cell migration by hyperpolarisating 
plasma membrane as observe in excitable cells (Chantôme et al., 2009). This new function of 
the SK3 channel in melanoma cells was revealed using pharmacological and molecular 
biology approaches (there is no specific inhibitor of SK3 channel); stable silencing SK3 
protein inhibited melanoma cell migration, which became insensitive to apamin and 
inversely, a stable expression of SK3 in SK3-non expressing melanoma cells, enhanced their 
migration that became sensitive to apamin. If patch-clamp experiments reveal that SK3 
channel hyperpolarises plasma membrane of melanoma cells, increasing external K+ 
concentration reduced only SK3-dependant cell motility (Chantôme et al., 2009). All of these 
experiments demonstrate that SK3 channel promotes melanoma cell migration through its 
primary function as an ion channel. Since the KCa3.1 channel had no effect on melanoma 
cell migration despite actively regulating membrane potential we propose that the increase 
of melanoma cell migration by hyperpolarisation is SK3 dependent. 
The mechanism by which SK3 channel regulates melanoma cell migration may involve 
[Ca2+] oscillations (frequency, amplitude) regulation (Fig. 2). Indeed, an increase of K+ efflux 
shifts the membrane potential towards negative values (hyperpolarization) and 
consequently increases the Ca2+ driving force (Potier et al., 2006; Rao et al., 2006; Rao et al., 
2002). Inversely, a reduction of SK3 channel activity may depolarize the plasma membrane 
and reduce Ca2+ entry. That further suggests that SK3 channel interacts in cooperation with 
a specific complex such as voltage-independent-calcium channel like transient-receptor -
potential (TRP) that are known to be sufficient to activate Ca2+-regulated stimulatory 
pathways for cell migration (Louis et al., 2008; Rao et al., 2006; Waning et al., 2007; 
Wondergem et al., 2008). This needs to be elucidated. 
The ability of SK3 channel to promote cancer cell migration led us to create a patent that 
addresses the use of this protein as a tool for the in vitro screening of compounds that 
inhibits SK3-dependent cell migration and metastasis development (Potier et al., 2008). 
 
 
Fig. 2. Proposed model to explain how SK3 channel increase melanoma cell migration. The 
expression of SK3 protein lead to a functional SK3 channel that hyperpolarizes plasma 
membrane and increase Ca2+ entry through voltage-independent Ca2+ channels and 
intracellular Ca2+ concentration promoting cell migration 
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4.2 IKCa/KCa3.1/SK4 channel 
The KCa3.1 channel - composed of protein that is strictly expressed outside the central 
nervous system - is expressed in melanocytes and melanoma cell lines (Allen et al., 1997; 
Chantôme et al., 2009; Schmidt et al., 2010; Schwab et al., 1999; Tajima et al., 2006). This 
channel appears to be involved in the migration process by facilitating the retraction of the 
rear part of migrating cells through induction of local cell shrinkage (Schwab, 2001). 
Interestingly, the KCa3.1 channel was found to support melanoma inhibitory activity, a 
protein known to play a role in melanoma development, progression and metastasis 
formation (Schmidt et al., 2010). KCa3.1 channel was also found to be involved in non-
cancerous cell migration o (e.g. lung mast cells or human coronary smooth muscle cells) 
(Cruse et al., 2006; Toyama et al., 2008). Low dose of TRAM-34 (that specifically blocks 
KCa3.1 channel and depolarize cell membrane) and high dose of TRAM-34 or clotrimazole 
(that inhibit KCa3.1 channels and other voltage dependent K+ channels (Wulff et al., 2000)) 
did not impair melanoma cell migration (Chantôme et al., 2009). This indicates that KCa3.1 
channel activity has no effect on melanoma cell migration despite its active role in 
regulating membrane potential. 
4.3 Voltage-gated potassium channel hERG  
The human ether-à-go-go (eag) related gene channel hERG, also known as KCNH2 (gene) 
and Kv11.1 (protein), is a member of the related Eag-like family of K+ channel. hERG 
encodes a voltage-dependent K+ channel that normally regulates cardiac repolarisation 
(Sanguinetti et al., 1995; Trudeau et al., 1995). The channel presents a unique activation 
kinetic: upon depolarisation, the channel opens but very rapidly inactivates, shutting down 
the K+ efflux. During the repolarisation phase of cardiac action potential, the recovery from 
inactivation is faster than the deactivation, the resulting K+ tail current shortening the action 
potential duration and decreasing the firing frequency (Schwarz & Bauer, 2004). In contrast 
to Eag1, hERG channel is expressed in a variety of tissue but its expression in melanocyte 
has not been investigated in our knowledge, but it is found in many tumour cells of 
different origins and exert pleiotropic effects in cancer cells (Asher et al., 2010). In a series of 
recent studies, the team of Arcangeli has proposed hERG as a biological marker of 
leukaemia and several solid tumours and leukaemia. HERG is involved in cell proliferation, 
apoptosis resistance and cell invasion (Bianchi et al., 1998; Lastraioli et al., 2004; Pillozzi et 
al., 2002). Several hERG isoforms interacting to modulate subunit trafficking and functional 
channel membrane expression are linked to the cell cycle and the differentiation state of 
myeloid and neuroblastoma cells (Crociani et al., 2003; Guasti et al., 2008). Strikingly, hERG 
forms membrane macromolecular complexes with β1 integrins and the growth factor 
receptor FLT1. Cell adhesion to extra cellular matrix components such as fibronectin 
activates hERG and enhances adhesion receptor signalling such as tyrosine phosphorylation 
of focal adhesion kinase (Cherubini et al., 2005). In AML, the hERG1b isoform is recruited by 
the β1 integrin to promote FLT1 signalling. In vivo, hERG positive blasts are more efficient 
in invading the peripheral circulation and the extramedullary sites after engraftment into 
immunodeficient mice (Pillozzi et al., 2007). In acute lymphoblastic leukaemia, hERG 
expression enhances chemotherapy-induced apoptosis and drug resistance (Pillozzi et al., 
2011). In the MDA-MD-435s cell line, hERG participates to cell migration and proliferation 
through a MAP kinase/c-fos pathway. HERG blockers such as E-4031 or silencing by siRNA 
reduce both proliferation and migration, but surprisingly no current can be recorded, 
demonstrating that hERG is no functional as a K+ pore (Afrasiabi et al., 2010). Similar to 
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Eag1, hERG might mediate at least in part, its effects on cell cancer behaviour through non-
pore associated mechanisms. However, concerning the role of hERG in melanoma cell 
behaviour, data must be used cautiously since the cancer origin of MDA-MD-435s cell line is 
rather a basal-type breast cancer, even if MDA-MD-435s cells have a genetic basis similar to 
melanomas (Chambers, 2009; Rae et al., 2007; Sellappan et al., 2004). 
4.4 Voltage-gated potassium channel Kv1.3 
Kv1.3 (KCNA3) channels, another voltage-dependent K+ channel, have been first isolated 
from Jurkat T cells (Chandy et al., 2004; DeCoursey et al., 1984). By regulating the resting 
membrane potential and thus the Ca2+ driving force, this channel modulates NFAT (Nuclear 
Factor of Activated T cells) translocation and mitogenesis (Chandy et al., 2004). The 
expression level of Kv1.3 is unchanged or down regulated depending the cancer type. In 
breast adenocarcinoma, the promoter of the gene encoding the channel is methylated 
leading to a down regulation of Kv1.3 expression (Bielanska et al., 2009; Brevet et al., 2009). 
In the LOX melanoma cell line, Kv1.3 is associated to the β1-integrin subunit and might 
regulate tumour cell behaviour by influencing macro molecular complexes linked to 
integrins (Artym & Petty, 2002). In this way, Kv1.3 may have in melanoma cells the same 
function as hERG in leukaemia cells. 
4.5 Voltage-gated sodium channel Nav1.6 
Voltage-gated Na+ channels (NaV) are known to be responsible for transient inward Na+ 
currents in excitable cells in which they are responsible for the initial membrane 
depolarisation triggering and allowing the propagation of action potentials. They are 
blocked by the highly specific blocker tetrodotoxin (TTX) at different doses from nM to µM 
concentrations depending on isoforms and numerous pharmacological modulators of these 
channels have been developed by pharmaceutical companies for the treatment of pain or 
some cardiovascular diseases. 
The expression and activity of pore-forming alpha subunits of NaV have been linked to 
cancer cell migration/invasion originating from different tissues such as prostate (Diss et al., 
2001), breast (Fraser et al., 2005; Gillet et al., 2009; Roger et al., 2003), lung (Onganer & 
Djamgoz, 2005; Roger et al., 2007), cervix (Diaz et al., 2007), colon (House et al., 2010), 
ovaries (Gao et al., 2010). Depending on the tissues, pore-forming isoforms responsible for 
the Na+ current and for the cellular effect, i.e. the enhancement of cancer cell invasiveness are 
different, but appeared not to be linked to the triggering of action potentials, but rather to 
the cystein cathepsin-dependent extracellular matrix degradation (Gao et al., 2010). In 
human breast cancer cells MDA-MB-231, NaV1.5 functioning enhances the activity of the 
Na+/H+ exchanger type 1 (NHE-1) responsible for the perimembrane space acidification and 
thus promoting cystein cathepsins proteolytic activity (Brisson et al., 2011). 
In melanoma there are, to our knowledge, only two studies reporting the expression of NaV. 
The first one was carried out in the late 1990’s, on human melanoma cell lines, and had for 
goal to identify the electrophysiological characteristics of these cells (Allen et al., 1997). In 
this first article, TTX-sensitive (Kd ~ 6 nM) voltage-gated Na+ currents were recorded in 
about 40% of C8161 and C8146 cells tested. However, the role of these currents in melanoma 
biology was not identified. 
Later on, a study performed by Carrithers and coll. on HTB-26 invasive human melanoma 
cells indicated the expression of a splice variant lacking the exon 18 of the Na+ channel 
SCN8A gene, encoding the NaV1.6 protein (Carrithers et al., 2009). The activity of this 
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channel, mainly identified in intracellular vesicles, was found to be involved in melanoma 
invadopodia formation and cell invasiveness. This effect was proposed to depend on 
intracellular Ca2+ regulation through mitochondrial Na+/Ca2+ exchangers and to the rapid 
remodelling of F-actin cytoskeleton. This regulation of intracellular Na+ and Ca2+ homeostasis 
could also modulate the activity of pH regulators, such as NHE-1, demonstrated to be key 
regulators of melanoma invasion at the front of invasive cells (Stock et al., 2007; Stock & 
Schwab, 2009). 
5. Ion channel modulators as therapeutic targets 
Sigma1 receptors as ion channel regulatory partners in cancer cells 
Targeting ion channels abnormally expressed in cancer cells represents an exciting new 
perspective for cancer treatment. Nevertheless, because these ion channels are also expressed 
in the heart or brain, the use of toxins is potentially hazardous and the therapeutic challenge 
is to specifically target ion channels in tumours. Characterizing the specific interactors of ion 
channels in cancer cells opens an interesting alternative strategy, providing the possibility to 
target ion channels through these tumour-specific partners (Arcangeli et al., 2009). The 
Sigma 1 receptor (Sig1R) is a 25 kDa protein anchored to the different cell membrane 
systems including ER, mitochondria, nucleus and plasma membranes (Tsai et al., 2009). The 
structure shares no homology with other mammalian proteins (Hanner et al., 1996) and 
includes two putative transmembrane domains (Su et al., 2010). Sig1R is distributed in the 
brain and peripheral tissues such as liver, kidney, ovaries or testis. Sig1R binds a large panel 
of exogenous drugs such as antipsychotics, opioids, antidepressants (sigma ligands) but also 
interacts with endogenous steroids (cholesterol and progesterone). Since the introduction of 
the concept thirty years ago (Martin et al., 1976) the function associated to Sig1R, mainly 
studied through the effects produced by sigma ligands, has been representing a challenging 
question. Sig1R have been involved in a huge number very different functions covering 
nociception, memory, drug addiction, cell electrical activity, apoptosis, cell cycle or immune 
response. Despite the abundant literature generated so far, the primary molecular mechanism 
governed by Sig1R to achieve those different functions has been missing. Recently, Su & 
Hayashi demonstrated in neuroblastoma cells that Sig1R physically associates to the 
chaperone Bip at the mitochondria-associated ER membrane (MAM) where it regulates Ca2+ 
fluxes between ER and mitochondria through the stabilisation of IP3 receptors (Fig. 3) 
(Hayashi & Su, 2007). From these finding, the emerging concept of the Sig1R as an inter-
organelle signalling modulator activated either by ligands or cell stress was proposed (Su et 
al., 2010). On the other hand, Sig1R interacts with various molecular families of ion channels 
including Kv, Cav, Nav, VRCC, NMDA or Asic channels (Herrera et al., 2008; Johannessen 
et al., 2009; Renaudo et al., 2007; Renaudo et al., 2004; Soriani et al., 1999a; Soriani et al., 
1999b; Soriani et al., 1998). Interestingly, sigma receptors are overexpressed in many cancer 
cell types and the protein is now considered as a tumour biomarker (Aydar et al., 2006; 
Aydar et al., 2004). Many efforts have been done since the early 90’s to develop specific 
sigma ligands for medical imagery and therapeutic applications (Collier et al., 2007). In 
particular, amine-amide-dithiol-[99mTc]oxotechnetium(V) complexes have been proposed 
as in vivo diagnostic agents for melanoma and its metastasis, with a high tumour uptake 
and significant tumour/non-tumour ratio (Friebe et al., 2001). Recently, sigma ligands have 
been used to develop nanoparticles that can systemically deliver siRNA into the cytoplasm 
of B16F10 murine melanoma cells, which express the sigma receptor. The targeted 
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nanoparticles containing c-Myc siRNA sensitized B16F10 cells to paclitaxel (Taxol), inducing 
a strong decrease in cell growth. Treatments of c-Myc siRNA in the targeted nanoparticles 
also showed significant inhibition on the growth of MDA-MB-435 tumour (Chen et al., 
2010). Last, the sigma1 ligand 4-IBP decreases melanoma cell migration in vitro (Megalizzi et 
al., 2007). These data raise the question of the function of sigma receptors in cancer cells. 
Recently, we have demonstrated that sigma ligands inhibit cell cycle by inhibiting both Kv 
and volume regulated chloride channels (VRCC) in leukaemia and small cell lung 
carcinoma cells. The alteration of these ion channels by sigma ligand provokes a reduced 
capacity of cell to regulate their shape and volume during at the G1/S checkpoint, leading to 
an accumulation of p27kip1 and the downstream reduction in cyclin A levels (Renaudo et 
al., 2004; Renaudo et al., 2007). Moreover, we found that the overexpression of Sig1R in 
cancer cells enhanced per se apoptosis resistance by reducing VRCC activation kinetics, this 
channel controlling the apoptosis volume decrease (Renaudo et al., 2007). These finding 
suggest that sigma1 receptors are involved in the control of cell shape through K+, Cl- and 
water fluxes, a key factor for cancer cell division, apoptosis and migration (Habela et al., 
2009; Rouzaire-Dubois et al., 2000). Interestingly, Su and coll. have shown that Sig1R 
regulate IP3 receptors following a cell stress (Tsai et al., 2009). It can then be suggested that 
the ion channel regulatory function of Sig1R is specifically potentiated in cancer cells when 
compared to healthy cells. However, if the effects of exogenous sigma receptor ligands on 
several ion channels are well described, the innate role of Sig1R regarding ion channel 
function or expression needs to be studied. 
 
 
Fig. 3. Sig1R modulation on ion channels: A putative model. Under ER stress, Sig1R 
stabilizes IP3 receptors and regulates Ca2+ influx from ER to mitochondria to protect cells 
from apoptosis (Hayashi & Su, 2007). Sig1R also modulates VRCC and Kv channels to 
reduce AVD, enhancing apoptosis resistance (Renaudo et al., 2004; Renaudo et al., 2007). 
Sig1R might target other channels such as Nav or SKCa 
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Altogether, these data suggest that Sig1R might be a potential therapeutic target in 
melanoma. While the function and mechanisms of action of Sig1R in melanoma remain to be 
determined, it can be speculated that the protein regulates various ion channels of interest 
involved in proliferation and/or invasiveness. Sigma ligands might then be used to inhibit 
these channels specifically in melanoma. 
6. Channel proteins and anti-cancer therapy for melanoma 
In summary, there are at least 8 channels or groups of channels that have been suggested as 
anticancer or antimetastatic therapeutic targets: Store-Operated Channels (SOCs) (including 
Stim 1 and Orai1); P2X7R; TRPM8; sodium pump (Na+,K+-ATPase); SK3/KCa2.3 channel; 
the VGKC Eag1; Nav1.6 and Sig1R. In absence of the identification of cancer-associated 
mutant ion channel molecules, there is no ideal and specific target in the field of ion 
channels, like the other potential therapeutic targets corresponding to wild-type molecules. 
The Sig1R does not follow this rule because it is suspected of having cancer-specific 
interactions with ion channels. Identification of such specific cancer associated interactions of 
Sig1R with channel partners would be very attractive to target tumour cells because they 
offer the possibility of minimizing toxic effects to non-tumour cells. As tumour eradication 
is obviously preferable to tumour arrest, targeting ion channels involved only in cell 
proliferation, which would help rather to limit tumour expansion than to eliminate it, is 
conceivable in combination to other therapies. However, the inhibition of melanoma SOC 
channels would be helpful to overcome resistance to chemotherapy-induced apoptosis, and 
inversely the activation of P2X7R and TRPM8 or inhibition of sodium pump might lead to 
cell death. Finally, since metastatic melanoma is almost incurable because of lack of effective 
anti-metastatic therapies, the most promising ion channel candidates for melanoma are 
those that would target cellular processes involved in metastasis occurrence. Fortunately at 
least two ion channel candidates belong to this category; SK3/KCa2.3 and Nav1.6 channels. 
Due to their cellular localisation, modulation of ion channels is easy and has many 
advantages that make it an ideal anti-cancerous therapeutic approach (e.g. extracellular 
targeting, excepted for stim1; restricted metabolic effects). The recent robotisation of patch 
clamp method, the electrophysiological method that measured ion channel activity, greatly 
facilitates the screening of new anti-channel drugs. The exploitation of anti-channel drug as 
anticancer drugs is currently still underdeveloped, may be due to their unintentional side 
effects on non-tumour tissues. This is specifically true for channels expressed in 
cardiomyocyte that might cause undesirable cardiac side effects (e.g. hERG). Arcangeli and 
coll have written an excellent review that addresses the altered expression of ion channels in 
cancer, their pharmacological blockers potentially usable in therapy and the numerous side 
effects predicted or known related to their inhibition (Arcangeli et al., 2009). Thus, before 
developing new therapeutic approaches through new biological targets, some prerequisites 
must be considered to predict or avoid some side effects (expression level and biological 
function between tumour and non-tumour tissue). With regard to melanoma, our current 
knowledge are relatively fragmented and remained to be deepening, but for some channels 
such as SK3, TRPM8, sodium pump, Nav1.6, Sig1R, recent data are sufficient to consider 
them as good druggable targets. Note that for two of them, TRPM8 and sodium pump, their 
expression in human clinical samples has already been demonstrated. If multiple cellular 
targets of melanoma have been identified, pharmacological drugs remain to be developed. 
Note that most ion channels belong to large families of channels and that it is relatively 
difficult to develop specific agonists or antagonists for one particular channel. In oncology 
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the concept to use ion channel modulators in therapy is recent but might be compensated by 
the active development of these modulating agents in other medical disciplines (e. g. 
neurology, cardiology). 
Actually, there is an increasing list of recent patents related to the use of ion channels 
modulators in anticancer therapy (Le Guennec et al., 2007; Villalonga et al., 2007). To date, 
only KCa3.1/SK4 blockers have been proposed for the treatment of prostate, pancreatic, and 
endometrial cancer, based on their ability to inhibit in vitro cell proliferation. So far only few 
blockers, particularly the clotrimazole analogue to TRAM-34 (Patent WO/2007/033307, 
22.03.2007), emerge as promising anticancer drugs, presumably as adjuvant of cancer 
therapy. In this regard, SK3 channel has been proposed as a tool for the in vitro screening of 
compounds that might inhibit SK3-dependent cell migration and metastasis development 
(WO/2008/015267). In regards to Sig1R, the number of patents in the field of cancer is 
rather low, and concerns mainly imagery (PET scan) for the early detection of tumours. We 
believe that the identification of cancer-associated interaction between Sig1R and a specific 
ion channels might propose the more specific of anti-cancer therapies. Indeed if Sig1R 
represent a promising target for cancer therapy, physical and functional links with ion 
channels expressed in melanoma require to be explored, especially for the putative  
coupling with Nav1.6, Kv1.3, Eag1 and SK3 channels, channels that have been already link 
to some behaviour of melanoma cells (see above). To our knowledge, no patented molecules 
or drugs has been established for its ability to recognize a cancer-associated complex of 
Sig1R/ ion channel. 
7. Conclusion - perspectives 
In conclusion, there is now strong evidence that numerous ion channels play important 
roles in carcinogenesis in participating actively to determine the common features of cancer 
cells, such as unlimited proliferative potential, evasion of cell death, angiogenesis, reduction 
of adhesion, invasion and metastasis development. In melanogenesis, additional research 
remains to be done such, as clinical relevance related to channel type expression, prognostic 
information, discovery of melanoma-specific complexes, development of more potent and 
specific inhibitors. To expect reaching the ideal specificity of a new drug toward melanoma, 
effort might be done in the identification of cancer-associated mutants of ion channel 
molecules, in the identification of specific complexes of channels /partners or channels / 
subunits associated to melanoma. Nevertheless, the important work of the cell physiologists, 
oncologists, chemists, biologists and pharmacologists has shown the promising interest of 
ion channel as therapeutic targets. 
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